---
title: "VK2735 in Chronic weight management: Access and distribution"
description: "Formulary evidence on VK2735 in Chronic weight management: Access and distribution. Topics: Commercial manufacturing and supply agreement; Commercial organization and launch preparation; Planned distribution channels: cash pay, direct-to-consumer, and direct-to-employer; Medicare coverage: GLP-1 Bridge program; 2 further topics. 6 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/access-and-distribution"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial manufacturing and supply agreement

> “today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an industry-leading contract development and manufacturing organization (CDMO), covering both the active pharmaceutical ingredient (API) and final finished product supply for its VK2735 program for obesity.”
> “Under the terms of the agreement, Viking has secured dedicated capacity for the manufacture of, and a commitment to supply annually, multiple metric tons of VK2735 API.”
> “These API and final finished product capacities are further expandable at Viking's option.”
> “In exchange for dedicated API and fill/finish capacity, Viking will make prepayments totaling $150 million, to be paid over the period from 2025 to 2028. Prepayments will be credited against future orders.”

Source: [Viking Therapeutics CordenPharma agreement release (2025)](https://ir.vikingtherapeutics.com/2025-03-11-Viking-Therapeutics-Signs-Broad-Manufacturing-Agreement-With-CordenPharma-to-Support-Commercialization-of-VK2735)

<a id="topic-2.1.2.11-2"></a>

### Commercial organization and launch preparation

> “today announced the appointment of Neil Aubuchon as chief commercial officer.”

Source: [Viking Therapeutics chief commercial officer appointment release (2026)](https://ir.vikingtherapeutics.com/2026-01-07-Viking-Therapeutics-Announces-Appointment-of-Neil-Aubuchon-as-Chief-Commercial-Officer)

> “But we have an SVP of commercial who has been involved in multiple obesity drug launches. We've got a VP of market access underneath him. We've got a VP of medical affairs. We have health economics and outcomes research.”
> “But we've added staff just in the last quarter or so in tech ops, in CMC, supply chain, in quality and compliance.”

Source: [Viking Therapeutics third quarter 2026 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/714458-q3-2026/)

<a id="topic-2.1.2.11-3"></a>

### Planned distribution channels: cash pay, direct-to-consumer, and direct-to-employer

> “Second is, as a smaller company, one of the challenges smaller companies have is access. 50% of the business now is in cash.”
> “They are creating what they call a direct-to-employer option, where they are treating this like a gym membership, where they are subsidizing let us say $100 or $150 a month to their employees, and the employees are paying the incremental, call it whatever, $150 a month out of pocket. In that model, patients can go to whatever product they want. There is no formulary.”
> “The other thing is that there are companies out there now that are doing direct-to-consumer engagement and marketing, frankly better than big pharma companies are doing. All of those companies want to work with us.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “To be able to partner with direct-to-consumer companies, and we're talking to just about all of them now gives us a really good opportunity.”
> “Again, the great thing about this is that it's not through PBM, so there's no rebate wall that we have to worry about.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.2.11-4"></a>

### Medicare coverage: GLP-1 Bridge program

> “We are also seeing the Medicare GLP-1 Bridge program go extremely well. The uptake, at least early days, has been very positive. We would expect to have access to that.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

> “Finally, Medicare is going to be covering these drugs as of July 1st.”
> “I think that that channel's going to be open to us as well.”

Source: [Viking Therapeutics Jefferies conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/678533-jefferies-global-healthcare-conference-2026/)

<a id="topic-2.1.2.11-5"></a>

### Commercialization rights and partnering

> “Neil is a perfect fit to lead our commercialization strategy for VK2735, including engagement with potential strategic partners, representing a key step in our preparation for commercial success”

Source: [Viking Therapeutics chief commercial officer appointment release (2026)](https://ir.vikingtherapeutics.com/2026-01-07-Viking-Therapeutics-Announces-Appointment-of-Neil-Aubuchon-as-Chief-Commercial-Officer)

> “As far as partnering, there are a lot of different options available to us, and I think those companies, they provide a pretty good avenue to access the market, but probably not something that we're going to disclose at this point.”

Source: [Viking Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/401860-q4-2025/)

> “First of all, we've stated publicly that we are always open to strategic collaborations, so whatever we do is not going to get in the way of that. But at the same time, we have to plan for the business as if we're running it ourself.”

Source: [Viking Therapeutics Morgan Stanley conference transcript (2026)](https://stockanalysis.com/stocks/vktx/transcripts/744429-morgan-stanley-24th-annual-global-healthcare-conference/)

<a id="topic-2.1.2.11-6"></a>

### Third-party payer reimbursement risk stated by the company

> “Although we believe that there will be a significant cash pay market for obesity drugs, there certainly would be a much larger obesity market with reimbursement from third-party payors and likely no viable commercial market for our other drug candidates, if approved, without reimbursement from third-party payors.”

Source: [Viking Therapeutics Form 10-Q third quarter (2026)](https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm)

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or distribution network

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
